…reflection of lupus activity than conventional C3 and C4 levels.sTCC were particularly informative for both active SLE and nephritis…
All extracted drugs
Showing 601–660 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Articles mentioning drugs
10,506 articles · page 68 of 876…vity, Lupus nephritis. She was treated with Methylprednisolone, Hydroxychloroquine, Azathioprine, one infusion of Belimumab. After 18 month evolut…
…d HCQ 400 mg/day. In August 2025, due to inadequate efficacy of rituximab (3 g), intolerance to MMF, and limitations on IS (due to leukop…
…thematous (SLE). We report a case of recurrent ALP treated with anifrolumab.Methods A 47-year-old man presented in August 2022 with progres…
… refractory to multiple therapies, highlighting the response to rituximab. Prior reports support the benefit of rituximab in SLE-associat…
…and suggest that formal remission does not always coincide with GC withdrawal. Personalized management remains essential to optimi…
…l (66.7%), azathioprine (11%) and tacrolimus (11%)]. 2 received Belimumab monotherapy.Baseline combined SLEDAI was 10.2±3.9 (range 4-16),…
…Objectives Belimumab (BEL) is a B-cell modulator targeting the central immunopathoge…
… this small real-world cohort of RTX-refractory/intolerant SLE, OBZ yielded promising responses, including in lupus nephritis, with…
…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…
…an age 31 years; median disease duration 9 years), 94% received hydroxychloroquine and 70% received immunosuppressants. Of those tapering PDN (n=7…
… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…